| | | | | | | | | | | | | | | | | | | | | | | |
|
|
|
|
| 2006D-0383
|
| Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious Diseases
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FDA Comment Number :
|
| EC2409
|
|
|
|
|
| Submitter :
|
| Mr. Ron and Sandra Grefke
|
| Date & Time:
|
| 12/01/2006 08:12:24
|
|
|
|
|
| Organization :
|
| Mr. Ron and Sandra Grefke
|
|
|
|
|
| Category :
|
| Individual Consumer
|
|
|
|
|
| Issue Areas/Comments
|
|
|
|
|
|
| GENERAL
|
|
|
|
|
|
|
|
| GENERAL
|
|
|
|
|
|
|
|
| We support the FDA recommending that pharmaceutical companies use these cells from non-controversial sources instead of cells derived from aborted children.
|
|
|
|
|
|
|
|
|
|
|
|
|
|